Use of heat shock protein inhibitorsfor the reduction of hair growth

Details for Australian Patent Application No. 2005237545 (hide)

Owner The Gillette Company

Inventors Ahluwalia, Gurpreet S.; Botchkareva, Natalia; Shander, Douglas

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-B-2005237545

PCT Pub. Number WO2005/105023

Priority 10/833,673 27.04.04 US

Filing date 25 April 2005

Wipo publication date 10 November 2005

Acceptance publication date 18 September 2008

International Classifications

A61K 8/49 (2006.01) Cosmetics or similar toilet preparations

A61Q 7/02 (2006.01) Preparations for affecting hair growth - Preparations for inhibiting or slowing hair growth

Event Publications

23 November 2006 PCT application entered the National Phase

  PCT publication WO2005/105023 Priority application(s): WO2005/105023

18 September 2008 Application Accepted

  Published as AU-B-2005237545

30 October 2008 Application for Amendment

  The nature of the amendment is: Amend the invention title to read from Use of heat shock protein inhibitorsfor the reduction of hair growth to Use of heat shock protein inhibitors for the reduction of hair growth. Address for service in Australia - Phillips Ormonde & Fitzpatrick Level 22 367 Collins Street Melbourne VIC 3000

5 February 2009 Amendment Made

  The nature of the amendment is: Amend the invention title to read Use of heat shock protein inhibitors for the reduction of hair growth

12 February 2009 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005237546-Therapeutic antimicrobial compositions and methods

2005237543-Statins for the treatment of ocular hypertension and glaucoma